ProfileGDS5678 / 1438687_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 45% 44% 44% 65% 43% 48% 43% 43% 42% 43% 43% 41% 44% 44% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.1028945
GSM967853U87-EV human glioblastoma xenograft - Control 23.0288444
GSM967854U87-EV human glioblastoma xenograft - Control 33.0211344
GSM967855U87-EV human glioblastoma xenograft - Control 43.8900165
GSM967856U87-EV human glioblastoma xenograft - Control 52.9473543
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.241348
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0721543
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.9988743
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9498442
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.974443
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.9977143
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.9047541
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.0249444
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.0085944